Agios Pharmaceuticals, Inc.
$33.09
The Read: Agios's stock showed modest gains on strong Pyrukynd sales and positive pipeline updates but faced sharp declines when legal investigations into Mitapivat trial data overshadowed regulatory approvals, with mixed reactions persisting amid pending FDA decisions.
AGIO
Hover to view data
No Data